Titan Medical Inc.
TMDIF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | -0.27 | 1.82 | 1.54 |
| FCF Yield | 2.55% | -1.49% | -2.19% | -0.05% |
| EV / EBITDA | 22.95 | -46.09 | -120.10 | -124.41 |
| Quality | ||||
| ROIC | 169.04% | 2,952.93% | -84.17% | -40.14% |
| Gross Margin | 98.95% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.67 | 0.65 | 2.46 | 0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.40% | -100.00% | – | – |
| Free Cash Flow Growth | 116.57% | 25.86% | -2,335.78% | 96.80% |
| Safety | ||||
| Net Debt / EBITDA | -0.82 | 0.04 | 2.23 | 0.99 |
| Interest Coverage | 46.66 | -290.52 | -166.02 | 4.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -504.94 | -2,651.13 | 151.54 | 1.24 |